Cerenome is trading at $3.30 (-10.33%) in after-hours trading after its second-quarter loss per share missed estimates.
- Cerenome reported a $9.0 million second-quarter net loss, or $1.31 per share, missing the $0.96-per-share consensus estimate.
- Revenue was $411,000, missing estimates by 60.86%.
- Operating loss widened to $9.1 million from $1.5 million year over year amid clinical-trial and commercial investment; the earnings release at the August 14, 2026 close is the clearest catalyst.